Artiva Bets on Cell Therapy to Conquer Refractory Rheumatoid Arthritis

SAN DIEGO, CA – March 10, 2026 – Artiva Biotherapeutics is making a strategic pivot, aiming its lead “off-the-shelf” cell therapy, AlloNK®, at one of the most challenging frontiers in autoimmune medicine: refractory rheumatoid arthritis (RA). The company announced its full-year 2025 financial results today, revealing a clear focus on advancing AlloNK® into a potential registrational trial, a move that could establish a new treatment paradigm for tens of thousands of patients who have exhausted other options.

Artiva confirmed it has a cash runway of $108.0 million, expected to fund operations into the second quarter of 2027. This financial stability will be crucial as the company approaches two major milestones in the first half of 2026: the release of initial clinical response data for AlloNK® in RA patients and a critical meeting with the U.S. Food and Drug Administration (FDA) to discuss a pivotal trial design.

“2025 was a year of strong execution as we advanced our AlloNK program, successfully enrolling patients in community settings across autoimmune indications and prioritizing refractory RA as our lead indication,” said Fred Aslan, M.D., president and chief executive officer of Artiva Biotherapeutics. “AlloNK has the potential to redefine the treatment paradigm for refractory RA by combining the durable efficacy of deep B-cell depletion with an outpatient-ready profile suitable for community rheumatology practices.”

A New Hope for a Difficult-to-Treat Disease

Rheumatoid arthritis is a chronic autoimmune disorder affecting over 1.3 million adults in the United States. While modern biologic and targeted therapies have transformed outcomes for many, a significant portion of patients—estimated to be over 150,000 in the U.S. alone—suffer from refractory RA. These individuals have failed to respond to at least two different classes of advanced drugs, leaving them with persistent pain, inflammation, and progressive joint damage.

For this population, real-world data shows that even the next line of therapy often yields disappointing results, with meaningful response rates hovering between just 10% and 20%. Artiva aims to shatter that ceiling by targeting the root of the problem: pathogenic B-cells. AlloNK® is an allogeneic, or “off-the-shelf,” Natural Killer (NK) cell therapy. It is designed to be administered in combination with rituximab, a monoclonal antibody that flags B-cells for destruction. AlloNK® enhances this process, known as antibody-dependent cellular cytotoxicity (ADCC), to achieve a much deeper and more consistent depletion of B-cells than rituximab alone.

Crucially, Artiva has demonstrated that this can be done safely and conveniently. Across 32 patients treated for various autoimmune diseases, including RA, the AlloNK® regimen was administered entirely in outpatient clinics. The therapy was well tolerated, with no reports of the severe side effects that can complicate other cell therapies, such as cytokine release syndrome (CRS) or immune-related neurotoxicity (ICANS).

This combination of potentially profound efficacy and an outpatient-friendly safety profile is at the heart of Artiva’s strategy. The company has already received FDA Fast Track designation for AlloNK® in this indication, underscoring the urgent unmet need.

From Oncology Success to Autoimmune Promise

Artiva's confidence in pursuing autoimmune disease is built on a foundation of success in oncology. The scientific rationale is straightforward: the same B-cells that drive certain lymphomas are also implicated in the pathology of autoimmune conditions like RA. Before pivoting to autoimmunity, AlloNK® demonstrated impressive durability in a Phase 1/2 trial for relapsed/refractory B-cell non-Hodgkin lymphoma.

In that trial, AlloNK® combined with rituximab achieved a 64% complete response rate, with a median duration of response that exceeded 19.4 months—a result comparable to approved autologous CAR-T therapies. This proved the therapy’s potent B-cell-depleting mechanism.

Early data from the autoimmune program reinforces this potential. Across patients treated, AlloNK® drove peripheral CD19+ B-cell levels to non-quantifiable depths by Day 13, as measured by a highly sensitive assay. Furthermore, the pattern of B-cell return was dominated by naïve and transitional cells, a sign of immune system “resetting” that has been observed with other deep B-cell depleting therapies and is believed to be key to achieving long-term remission.

A Calculated Strategy Backed by Financial Fortitude

The company's strategic focus is reflected in its latest financial report. Research and development expenses climbed to $69.5 million in 2025, up from $50.3 million in 2024, a direct result of accelerating clinical enrollment and preparing for late-stage trials. This increased spending contributed to a higher net loss of $83.9 million for the year. However, with $108.0 million in cash and investments, Artiva has secured a multi-year runway that extends past its most critical near-term catalysts.

This financial footing gives the company the stability to execute on its ambitious goals for 2026. “Our focus is to advance AlloNK from an early clinical program in the deep B-cell depletion space to what could become the first therapy in this class to initiate a registrational trial in RA, the autoimmune disease with the largest refractory population,” Dr. Aslan stated.

The upcoming data release will include results from at least 15 refractory RA patients, most with six or more months of follow-up, providing the first substantial look at the therapy's clinical efficacy in this challenging population. Positive results would provide strong momentum heading into discussions with the FDA about a pivotal trial.

Bolstering Leadership for the Road Ahead

To navigate the path to potential approval and commercialization, Artiva has significantly strengthened its leadership team and board of directors. The company recently appointed Subhashis Banerjee, M.D., a trained rheumatologist with deep experience in autoimmune drug development at firms like Bristol Myers Squibb, as its Chief Medical Officer. It also brought on Thad Huston as Chief Financial Officer to guide its capital strategy.

Furthermore, the board has been enhanced with the addition of Dan Baker, M.D., and Elaine Sorg, both of whom bring extensive experience in developing and commercializing blockbuster immunology drugs. These appointments signal a clear intent to build a company capable of not only developing an innovative therapy but also successfully bringing it to market.

As Artiva moves forward, the entire field of autoimmune therapy will be watching. The upcoming milestones in the first half of 2026 will be a critical test of whether the promise of off-the-shelf cell therapy can become a reality for patients battling refractory rheumatoid arthritis, potentially heralding a new era of treatment for autoimmune diseases.